Jefferies Financial Group Inc. Makes New $399,000 Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Jefferies Financial Group Inc. acquired a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 30,601 shares of the company's stock, valued at approximately $399,000. Jefferies Financial Group Inc. owned about 0.06% of Bicara Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Red Tree Management LLC acquired a new position in Bicara Therapeutics during the 4th quarter valued at about $55,230,000. Adage Capital Partners GP L.L.C. grew its stake in shares of Bicara Therapeutics by 171.9% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company's stock worth $37,893,000 after acquiring an additional 1,375,265 shares during the last quarter. Braidwell LP increased its holdings in shares of Bicara Therapeutics by 20.7% during the fourth quarter. Braidwell LP now owns 2,000,659 shares of the company's stock valued at $34,851,000 after acquiring an additional 343,059 shares in the last quarter. Deep Track Capital LP increased its holdings in shares of Bicara Therapeutics by 151.0% during the fourth quarter. Deep Track Capital LP now owns 2,000,000 shares of the company's stock valued at $34,840,000 after acquiring an additional 1,203,148 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Bicara Therapeutics by 0.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,547,180 shares of the company's stock valued at $26,953,000 after purchasing an additional 8,246 shares during the last quarter.

Bicara Therapeutics Stock Performance

BCAX remained flat at $10.20 during midday trading on Friday. The company's stock had a trading volume of 194,114 shares, compared to its average volume of 326,701. The business has a fifty day moving average of $10.43 and a 200 day moving average of $11.98. Bicara Therapeutics Inc. has a 12 month low of $7.80 and a 12 month high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.28). Analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on BCAX. HC Wainwright dropped their target price on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Wall Street Zen lowered shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Wedbush restated an "outperform" rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research note on Friday, May 23rd. Finally, Wells Fargo & Company raised Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price objective on the stock in a report on Friday, May 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Bicara Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $31.86.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.